So far there are no specific medications for COVID-19. But some drugs and therapies have been proven to be effective in treating patients. Let's have a look at them.
[Photo/VCG]
1. Favipiravir
It is an antiviral drug developed in Japan to be used against many viruses built around ribonucleic acid - a substance essential for human life - including the novel coronavirus.
Chinese researchers have completed clinical studies of Favipiravir, which shows promising clinical efficacy in treating novel coronavirus pneumonia, Zhang Xinmin, head of the China National Center for Biotechnology Development, said on March 17.
Experiments have shown that patients treated with Favipiravir recovered more quickly and their lung conditions improved better than patients in the control group.
The Third People's Hospital of Shenzhen in Guangdong province conducted a clinical trial on 80 patients, with 35 receiving the drug. The results showed that patients who took Favipiravir tested negative within four days of treatment, whereas patients in the control group needed 11 days to test negative.
The lung conditions of 91.4 percent of the treated group improved as shown in chest imaging, compared with 62.2 percent of the control group, Zhang said.
In terms of safety, Zhang said it has shown no obvious adverse effects.
A worker checks tablets on a chloroquine phosphate production line in Nantong, Jiangsu province, in February. [Photo/Xinhua]
2. Chloroquine phosphate
Developed in the 1950s to treat malaria, the drug has shown the potential to inhibit coronavirus growth during in vitro tests.
Zhong Nanshan, China's leading epidemic control expert, said early clinical results show that severe patients have recovered more quickly after taking the medicine compared to other drugs.
The medicine is included in the latest guideline on diagnosis and treatment of COVID-19 patients released by the National Health Commission.
Copyright © The National Committee of the Chinese People's Political Consultative Conference.
All rights reserved. Presented by China Daily.